ALM013

ALM013 (also referred to as ALM-013) is an investigational drug candidate being developed by Almatica Pharma, a specialty pharmaceutical subsidiary of Alvogen, for the treatment of anxiety disorders. The asset has reportedly reached Phase 3 clinical development, although company pipeline visualizations suggest it may be in Phase 2. Almatica Pharma focuses on the central nervous system (CNS) therapeutic area, specifically psychiatry and neurology. As of current public disclosures, the specific active pharmaceutical ingredient, biological target, and modality of ALM013 remain proprietary and have not been released to the public.